We help build successful companies that are tackling autism and a range of neurodevelopmental conditions.

We help build successful companies that are tackling autism and a range of neurodevelop-mental conditions.

We are investors, entrepreneurs, human resource professionals, scientists, researchers, and physicians committed to identifying unmet needs across the continuum of autism and deploying venture capital to fuel solutions to those needs.

OPERATING TEAM

Christopher Male

Co-Founder & Managing Partner

Robert Sarrazin

Chief Investment Officer & Managing Partner

Ashok Srinivasan

Chief Science Advisor

Robbie Allen

Operating Partner

Lauren Ingram

Principal

Dan Tarman

Chief Communications Officer

Michelle He

Senior Associate

Nikhita Kulkarni

Associate, Investments & Investor Relations

INVESTMENT ADVISORY BOARD

The Investment Advisory Team provides transaction advisory analysis, networking opportunities, and guidance on growth strategy for AIF’s portfolio companies. Each advisor has been greatly affected by autism.

Johan Andresen

Owner & Chair, Ferd

 

Cuong Do

President, Samsung Corporate Strategy Group

Mike Edmonds

Senior Director, Microsoft

Jason Eichenholz, Ph.D.

Founder and Chairman, Jonathan’s Landing Foundation

Jennifer Frist

Philanthropist, Frist Center For Autism And Innovation At Vanderbilt University

Arun Gupta

Founder & CEO, Quartet, Accretive, The World Bank, McKinsey

Sarah Hassan

Healthcare Investor & Entrepreneur

Elizabeth Horn

Founder & CEO 2M, COMPASS

AIF Founding LP

Brian Jacobs 

Venture Capitalist Emergence, Moai Capital

Amanda Lukof

Special Needs Advocate

Bob Nelsen

Co-Founder & Managing Director, ARCH Venture Partners

Christopher Sugahara

Senior Vice President, Fairfield-Maxwell

Sean O’Sullivan

SOSV (IndieBio, Hax)

AIF Founding LP

Mike Smart

Partner, Dominus Capital

“Venture capital is the accelerant that brings breakthrough technologies into markets. With millions of kids and adults suffering from severe medical and physiological challenges due to autism, now is the time for the Autism Impact Fund.”

– Sean O’Sullivan, AIF Advisor & Founding LP

SCIENTIFIC ADVISORY BOARD

The Scientific Advisory Board encompasses individuals with deep expertise in autism, academia, and industry. Each advisor provides scientific review and strategic thinking for the AIF.

David Amaral, PhD

Director Of The Autism Center Of Excellence At UC Davis

Linda Avey

Managing Partner, Humain Ventures

Susan Bratton

(Former) President, Electrochem Solutions, an Integer Company

Larry Derose

Founder & CEO, AdvaStim, Inc.

Thomas Frazier, PhD

Professor of Psychology, John Carroll University

Richard Frye, MD, PhD

Director Of Autism Research, Arkansas Children’s Hospital

John Gaitanis, MD

Pediatric Neurologist, Hasbro Children’s Hospital

Jacob Hooker, PhD

Scientific Director, Lurie Center for Autism, Massachusetts General Hospital; Professor of Radiology, Harvard Medical School

Tom Insel, MD

Co-Founder, Mindstrong, NIH

Ian Marks

Global VP Life Sciences, Salesforce, GSK, Novartis, Roche

Krishnan Nandabalan, PhD

CEO, Founder, & President, InveniAI

Alison Singer

Co-Founder & President, Autism Science Foundation

Mike Snyder, PhD

Chair of Genomics, Stanford Medical School

Pramila Srinivasan, PhD

CEO of ChARM Health

Keivan Stassun, PhD

Director, Frist Center for Autism and Innovation at Vanderbilt University; National Medal of Science Laureate